This site contains promotional information intended only for healthcare professionals resident in the United Kingdom
Sign in
Sign in
Sign out

Information relating to specific disease areas aligned to Pfizer’s portfolio and other resources designed for Pfizer medicines.

See all Therapy areas

Explore Content

The content of this website has been produced in line with the INLYTA® (axitinib​​​​​​​) Summary of Product Characteristics for Great Britain. 
​​​​​​​
Prescribing Information for INLYTA® (axitinib) click here.  Adverse event reporting information can be found at the bottom of the page.

ByYourSideTM app 

FOR PEOPLE LIVING WITH CANCER AND THOSE WHO LOVE THEM

ByYourSideTM is a programme created by Pfizer Oncology that provides tools to help cancer patients manage their lives, regardless of tumour type or stage, as well as resources to support their loved ones. These resources can be downloaded using the QR code below or via the App Store and Google Play Store.

How ByYourSideTM supports your patients

BE INSPIRED

Life with cancer is different for everyone. There are many ways that patients go about their lives after a diagnosis. Patients can visit ByYourSide™ to read inspiring stories of hope, determination and
generosity.

GET SUPPORT

Patients can visit ByYourSide.co.uk or download the ByYourSideTM app to browse articles and resources designed to help them navigate and manage life with cancer.

LIVE WELL

Help your patients connect to their wellbeing with articles on relationships, nutrition, fitness and more.

Everything your patients need to help manage their treatment journey

Download the ByYourSideTM app
Download the ByYourSideTM app

Discover more about how ByYourSideTM can help your patients


Reference
  1. INLYTA® Summary of Product Characteristics for Great Britain click here. INLYTA® Summary of Product Characteristics for Northern Ireland click here.
PP-INL-GBR-0841 May 2022

Indication

  • INLYTA® is indicated for the treatment of adult patients with advanced renal cell carcinoma (aRCC) after failure of prior treatment with sunitinib or a cytokine1

For UK Healthcare Professionals*

These pages are not intended for patients or for members of the general public. The healthcare professional web pages contain promotional content.

I confirm that I am a healthcare professional* resident in the United Kingdom.

If you select 'No', you will be redirected to Pfizer.co.uk where you will be able to access reference information on Pfizer's prescription medicines.

*The ABPI Code definition for healthcare professional is members of the medical, dental, pharmacy and nursing professionals and any other persons who in the course of their professional activities may administer, prescribe, purchase, recommend or supply a medicine.

PP-PFE-GBR-3863. November 2021

Yes

No

OK, We will need you to sign in before we can determine if you are aligned with a Pfizer promotional colleague.This is an interstitial message to prompt a HCP before they login.

If you have already registered with pfizerpro.co.uk and select ‘yes’, you will be directed to the sign-in page where you will be required to enter your username and password.

Would you like to register or sign in now?